Completed PHASE2 INTERVENTIONAL 7-arm NCT04549376

Virucidal Effect of Povidone Iodine on COVID-19 In-Vivo (VEP-COV)

Virucidal Effect of Povidone Iodine on COVID-19 In-Vivo: an Open Label Randomized Clinical Trial

Sponsor: DR. MALA KHAN

Conditions COVID19

Interventions Placebo comparator: DW-NI Placebo comparator: DW-NS Povidone-Iodine 0.4% NI Povidone-Iodine 0.5% NI Povidone-Iodine 0.5% NS Povidone-Iodine 0.6% NI Povidone-Iodine 0.6% NS

Updated 5 times since 2020 Last updated: Jan 10, 2022 Started: Jul 1, 2020 Primary completion: Oct 20, 2020 Completion: Oct 30, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04549376, this PHASE2 trial focuses on COVID19 and remains completed. Sponsored by DR. MALA KHAN, it has been updated 5 times since 2020, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Feb 2022 — Jul 2024 [monthly]

Completed PHASE2

Status: Recruiting → Completed
Jan 2021 — Feb 2022 [monthly]

Recruiting PHASE2
Oct 2020 — Jan 2021 [monthly]

Recruiting PHASE2

First recorded

Jul 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

DR. MALA KHAN
Dhaka Medical College

Data source: Bangladesh Reference Institute of Chemical Measurements (BRICM)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Dhaka, Bangladesh